Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Current studies confirmed that the immune perioperative treatment with combination chemotherapy curative effect and safety of resectable NSCLC, but its short-term curative effect and long-term survival benefit remains to be further improved to explore the new way of immune combination therapy. Experimental study showed that the inhibition of PCSK9 could significantly increase in tumor cells of the immune response in mice, inhibit the PCSK9 enhanced anti-tumor immune response of mice can be further coordinate with immune checkpoint therapy, forming a lasting anti-tumor immune effect. There ar

Trial Details

NCT ID
NCT06467617
Phase
PHASE2
Sponsor
Beijing Chest Hospital, Capital Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • 18-75 years old, male and female;
  • ECOG PS 0-1;
  • Histologically or cytologically confirmed operable stage II-III NSCLC (stages II, IIIA, and T3N2M0 IIIB) according to the UICC and AJCC 8th edition…
  • With a measurable lesions (per RECIST 1.1 standard, tumor lesions on CT scan length to diameter 10 mm, or lymph node lesions on CT scans short diam…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →